SNDL Reports Q2 2026 Financial and Operational Results

EDMONTON – SNDL Inc. announced the completion of assets acquisition from Surterra Holdings, Inc. and its affiliates, collectively known as Parallel, a vertically integrated Cannabis operator with state-licensed operations in Florida, Texas, and Massachusetts. The deal was executed through a strict foreclosure agreement via CDXX TransCo, LLC. The transaction extinguished approximately $842 million of Parallel’s legacy debt and gave SNDL, through its Sunstream Bancorp joint venture, indirect majority economic exposure equivalent to 66.7% of TransactionCo’s equity and 69.4% of its debt.

The acquired U.S. platform includes 56 retail locations and three cultivation and manufacturing facilities. Florida anchors with 43 Surterra Wellness dispensaries from a single cultivation facility of approximately 175,000 sq. feet. Texas contributes 10 Goodblend locations – one of only three active licensed operators serving the state’s approximately 31.7 million residents. Massachusetts adds three NETA dispensaries and one 19,600-square-foot production facility. The deal extends SNDL’s Cannabis retail network to 249 stores, which the company claims the largest in the world by store count.

One accounting reality matters here. The closing does not have any immediate impact on SNDL’s financial reporting. The investment continues to be accounted for using the equity method under IFRS based on SNDL’s indirect economic exposure. A change in financial reporting will occur once SNDL is in a position to convert its current indirect exposure into a direct majority equity and debt exposure expected to result in operational control and the consolidation of TransactionCo’s medical business. Massachusetts recreational exposure is expected to remain deconsolidated unless and until Nasdaq, applicable law, and accounting standards permit a different treatment.

Second quarter 2026 financial and operational results showed net revenue of C$235.8 million, down 3.7% year-over-year, with gross profit of C$56.3 million and a gross margin of 23.9%, down 3.7% points. The company posted an operating loss of C$7.8 million, reversing operating income of $5.0 million in Q2 2025.

The sharpest deterioration came from Cannabis operations. Gross profit there was driven down by lower revenue across all segments and Jeeter production ramp-up costs, collapsing segment gross margin from 25.8% to 1.8%. Liquor retail same-store sales fell 6.2%, and segment operating income dropped by more than half year-over-year. Cannabis retail was the steadier performer – near-flat revenue at C$83.2 million with gross margin expanding 0.5% points.

Free cash flow was negative C$6.7 million in Q2 2026, primarily driven by the annual payment of the 2025 management incentive and a cash-in-transit increase – still an improvement of $1.2 million from the prior-year quarter. SNDL repurchased and cancelled 16.2 million common shares at a weighted average price of $2.02 in H1 2026. The company ended June 30 with C$183.2 million in unrestricted cash and zero debt.

The Parallel acquisition gives SNDL legally secured U.S. medical exposure, but it stays off the income statement until the Nasdaq conversion is complete. On the Canadian side, Jeeter launch costs gutted Cannabis operations margins in a single quarter: a self-inflicted wound, recoverable, but the market is watching. The clean balance sheet and active buyback program provide a runway most Cannabis operators can’t match. Execution now runs on two tracks: restoring production margins at home and completing the regulatory steps that would make SNDL the first Nasdaq-listed company to directly consolidate U.S. medical Cannabis operations. That milestone is within reach. How quickly it arrives determines the shape of the story from here.